Department of Surgery, Odense University Hospital, 5000, Odense C, Denmark.
Surg Endosc. 2011 Mar;25(3):804-12. doi: 10.1007/s00464-010-1258-9. Epub 2010 Jul 30.
The combination of endoscopic and laparoscopic ultrasonography (EUS-LUS) is accurate for resectability assessment of patients with upper gastrointestinal cancer (UGIC). But neither the ability of EUS/LUS to predict long-term prognosis nor the potential impact on patient survival using this selection strategy has been investigated. This prospective, single-center study evaluated whether pretherapeutic EUS-LUS stratification related to the prognosis in UGIC patients and whether patient selection by this strategy provided a prognostic outcome comparable with survival data from the literature.
Each patient had a pretherapeutic tumor node metastasis (TNM) stage and a resectability assessment assigned based on EUS-LUS findings. Survival curves were constructed and compared for each of the EUS-LUS TNM stage and resectability groups at the end of the observation period. Finally, the R0 resection rate, median, and 5-year survival rates were compared with the literature.
This study enrolled 936 consecutive patients with esophageal (n = 256), gastric (n = 273), or pancreatic (n = 407) cancer. A statistically significant survival difference (p < 0.01) between the different TNM stages and resectability groups predicted by EUS-LUS was observed regardless of the cancer type. The poor prognosis for the patients with irresectable or disseminated UGIC was accurately predicted by EUS and LUS. The R0 resection rate as well as the median and 5-year survival rates were comparable with data from the literature.
The pretherapeutic EUS-LUS patient stratification related significantly to the final prognosis for UGIC patients. An EUS-LUS-based patient selection strategy seemed to provide a prognostic outcome similar to data from computed tomography (CT)-based populations.
内镜超声检查(EUS)与腹腔镜超声检查(LUS)联合应用可准确评估上消化道癌症(UGIC)患者的可切除性。但尚未研究 EUS/LUS 预测长期预后的能力,以及使用该选择策略对患者生存的潜在影响。本前瞻性单中心研究评估了 EUS-LUS 分层与 UGIC 患者预后的相关性,以及该策略是否选择患者可提供与文献中生存数据相当的预后结果。
每位患者均根据 EUS-LUS 检查结果进行了治疗前肿瘤淋巴结转移(TNM)分期和可切除性评估。在观察期结束时,为每个 EUS-LUS TNM 分期和可切除性组构建并比较生存曲线。最后,比较 R0 切除率、中位数和 5 年生存率与文献数据。
本研究共纳入了 936 例连续的食管(n=256)、胃(n=273)或胰腺(n=407)癌患者。EUS-LUS 预测的不同 TNM 分期和可切除性组之间存在显著的统计学生存差异(p<0.01),无论癌症类型如何。EUS 和 LUS 准确预测了不可切除或播散性 UGIC 患者的不良预后。R0 切除率以及中位数和 5 年生存率与文献数据相当。
EUS-LUS 治疗前患者分层与 UGIC 患者的最终预后显著相关。基于 EUS-LUS 的患者选择策略似乎提供了与 CT 人群数据相似的预后结果。